Acceso usuarios
According to this study:
* Intraperitoneal chemotherapy used in combination with iv chemotherapy increased three-year survival rates in women with stage III ovarian cancer, compared with iv chemotherapy alone.
* But those receiving intraperitoneal and iv chemotherapy were more likely to need changes to their treatment regimen because of treatment-related toxicities than those receiving only iv chemotherapy.
* Although the use of intraperi-toneal and iv chemotherapy together has increased over the past decade, fewer than half of eligible patients receive it.
